Welcome, Guest |
TOPIC:
HCV New Drugs Blogspot 8 years 2 months ago #11459
This email address is being protected from spambots. You need JavaScript enabled to view it. forums.delphiforums.com/generichcvtx G 1a F-1 Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil 11/17/15 4 wk lab ALT 17 AST 16 <15 11/18/15 Started Harvoni 12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND 1/14/16 Fin. Tx 7/07/16 UND SVR 24 The following user(s) said Thank You: pat1 | |
HCV New Drugs Blogspot 8 years 2 months ago #11547
New Screening and treatment criteria from WHO: hepatitiscnewdrugs.blogspot.com/2016/02/...-in-updated-who.html Thousands recalled for hepatitis C test after NHS worker's diagnosis: hepatitiscnewdrugs.blogspot.com/2016/02/...epatitis-c-test.html Bristol-Myers Squibb (NYSE:BMY) Presents Data on All-Oral Hepatitis C Regimen: hepatitiscnewdrugs.blogspot.com/2016/02/...ysebmy-presents.html This email address is being protected from spambots. You need JavaScript enabled to view it. forums.delphiforums.com/generichcvtx G 1a F-1 Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil 11/17/15 4 wk lab ALT 17 AST 16 <15 11/18/15 Started Harvoni 12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND 1/14/16 Fin. Tx 7/07/16 UND SVR 24 | |
HCV New Drugs Blogspot 8 years 2 months ago #11566
That last article is curious considering BMS withdrew application for approval of asuneprevir (in combination with daclatavir) in Oct 2014 Because - Source - www.hepmag.com/article/asunaprevir-end-26284-925493039 I wonder what changed, as they are reporting higher SVR rates in this trial? M 61yo HCV+ ~ 30 yrs Gt1a F2 VL 223,000 ALT 54 AST 42 Tx start Sof/Dac 17Dec15. SVR4 at 7Apr16 ALT 22 AST 22 SVR12 at 9Jun16 ALT 23 AST 25 Melbourne, Australia | |
HCV New Drugs Blogspot 8 years 2 months ago #11662
Re Cirrhosis: 2/24/16 hepatitiscnewdrugs.blogspot.com/2016/02/...gy-therapeutics.html Re Zepatier: hepatitiscnewdrugs.blogspot.com/2016/02/...tier-vs-harvoni.html This email address is being protected from spambots. You need JavaScript enabled to view it. forums.delphiforums.com/generichcvtx G 1a F-1 Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil 11/17/15 4 wk lab ALT 17 AST 16 <15 11/18/15 Started Harvoni 12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND 1/14/16 Fin. Tx 7/07/16 UND SVR 24 | |
HCV New Drugs Blogspot 8 years 2 months ago #11677
Looks like the 2014 report relates to earlier trials for approval for use in US so probably consisted mostly of western patient profile whereas these latest late stage trial results are for an all Chinese patient profile. This differing result is possibly to be expected as various racial groupings show differing responses to the old interferon treatments and also susceptibility to fibrosis/cirrhosis. G3a since '78 - Dx '12 - F4 (2xHCC) 24wk Tx - PEG/Riba/Dac 2013 relapsed 24wk Tx - Generic Sof/Dac/Riba 2015/16 relapsed 16wk Tx - 12/01/17 -> 03/05/17 NS3/NS5a + Generic Sof SVR7 - 22/06/17 UND SRV12 - 27/07/17 UND SVR24 - 26/10/17 UND The following user(s) said Thank You: sonix | |
HCV New Drugs Blogspot 8 years 2 months ago #11805
Lots of good reading here: Indian Patent Challenge: hepatitiscnewdrugs.blogspot.com/2016/02/...enge-hearing-on.html ABBVIE RECEIVES CHMP POSITIVE OPINION FOR VIEKIRAX® (OMBITASVIR/PARITAPREVIR/RITONAVIR TABLETS) + EXVIERA® (DASABUVIR TABLETS) WITHOUT RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C IN GENOTYPE 1B: hepatitiscnewdrugs.blogspot.com/2016/02/...ositive-opinion.html This version of the Guidance has been updated to reflect several important developments, including the recent approval of elbasvir/grazoprevir: hepatitiscnewdrugs.blogspot.com/2016/02/...ir-hcv-guidance.html Why Americans pay so much more for drugs: hepatitiscnewdrugs.blogspot.com/2016/02/...-more-for-drugs.html Quoted from the above article. Steve Miller, chief medical officer of Express Scripts wrote: "The U.S. is 4.6 percent of the world's population, we're 32 percent of the world's drug revenue, and we're somewhere between 50 and 70 percent of world drug profitability," Miller said. "The United States has been spending money to protect the world for decades. We're now being asked to essentially fund all pharmaceutical drug development. ... We cannot continue to carry this burden." This email address is being protected from spambots. You need JavaScript enabled to view it. forums.delphiforums.com/generichcvtx G 1a F-1 Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil 11/17/15 4 wk lab ALT 17 AST 16 <15 11/18/15 Started Harvoni 12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND 1/14/16 Fin. Tx 7/07/16 UND SVR 24 The following user(s) said Thank You: zhuk | |
HCV New Drugs Blogspot 8 years 2 months ago #12033
Interesting... hepatitiscnewdrugs.blogspot.com/2016/02/...000-pill-for-10.html RE; Australia: hepatitiscnewdrugs.blogspot.com/2016/02/...now-as-cheap-as.html Lack of awareness, affordability, etc. hepatitiscnewdrugs.blogspot.com/2016/02/...-affordable-but.html This email address is being protected from spambots. You need JavaScript enabled to view it. forums.delphiforums.com/generichcvtx G 1a F-1 Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil 11/17/15 4 wk lab ALT 17 AST 16 <15 11/18/15 Started Harvoni 12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND 1/14/16 Fin. Tx 7/07/16 UND SVR 24 | |
HCV New Drugs Blogspot 8 years 2 months ago #12331
This email address is being protected from spambots. You need JavaScript enabled to view it. forums.delphiforums.com/generichcvtx G 1a F-1 Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil 11/17/15 4 wk lab ALT 17 AST 16 <15 11/18/15 Started Harvoni 12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND 1/14/16 Fin. Tx 7/07/16 UND SVR 24 | |
HCV New Drugs Blogspot 8 years 1 month ago #12502
The"Buyers' Club Era" article, among others: hepatitiscnewdrugs.blogspot.com/2016/03/...s-with-news.html?m=1 This email address is being protected from spambots. You need JavaScript enabled to view it. forums.delphiforums.com/generichcvtx G 1a F-1 Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil 11/17/15 4 wk lab ALT 17 AST 16 <15 11/18/15 Started Harvoni 12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND 1/14/16 Fin. Tx 7/07/16 UND SVR 24 The following user(s) said Thank You: pat1 | |
HCV New Drugs Blogspot 8 years 1 month ago #12570
Recommendations from John W. Ward, MD, director of the Division of Viral Hepatitis at the Centers for Disease Control and Prevention (CDC).: hepatitiscnewdrugs.blogspot.com/2016/03/...re-out-of-reach.html This email address is being protected from spambots. You need JavaScript enabled to view it. forums.delphiforums.com/generichcvtx G 1a F-1 Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil 11/17/15 4 wk lab ALT 17 AST 16 <15 11/18/15 Started Harvoni 12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND 1/14/16 Fin. Tx 7/07/16 UND SVR 24 The following user(s) said Thank You: pat1 | |
HCV New Drugs Blogspot 8 years 1 month ago #12672
From the CDC: Annual Report to the Nation: Cancer death rates continue to decline Increase in liver cancer deaths cause for concern hepatitiscnewdrugs.blogspot.com/2016/03/...ne-but-increase.html This email address is being protected from spambots. You need JavaScript enabled to view it. forums.delphiforums.com/generichcvtx G 1a F-1 Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil 11/17/15 4 wk lab ALT 17 AST 16 <15 11/18/15 Started Harvoni 12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND 1/14/16 Fin. Tx 7/07/16 UND SVR 24 | |
HCV New Drugs Blogspot 8 years 1 month ago #12812
Merck vs Gilead: hepatitiscnewdrugs.blogspot.com/2016/03/...tis-c-drugs.html?m=1 Insurers rail against exorbitant drug costs: hepatitiscnewdrugs.blogspot.com/2016/03/...t-high-cost.html?m=1 This email address is being protected from spambots. You need JavaScript enabled to view it. forums.delphiforums.com/generichcvtx G 1a F-1 Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil 11/17/15 4 wk lab ALT 17 AST 16 <15 11/18/15 Started Harvoni 12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND 1/14/16 Fin. Tx 7/07/16 UND SVR 24 | |
HCV New Drugs Blogspot 8 years 1 month ago #13055
Some good reading here in "HCV Next" hepatitiscnewdrugs.blogspot.com/2016/03/...g-gap-impact-of.html This email address is being protected from spambots. You need JavaScript enabled to view it. forums.delphiforums.com/generichcvtx G 1a F-1 Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil 11/17/15 4 wk lab ALT 17 AST 16 <15 11/18/15 Started Harvoni 12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND 1/14/16 Fin. Tx 7/07/16 UND SVR 24 | |
HCV New Drugs Blogspot 8 years 1 month ago #13145
This email address is being protected from spambots. You need JavaScript enabled to view it. forums.delphiforums.com/generichcvtx G 1a F-1 Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil 11/17/15 4 wk lab ALT 17 AST 16 <15 11/18/15 Started Harvoni 12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND 1/14/16 Fin. Tx 7/07/16 UND SVR 24 | |
HCV New Drugs Blogspot 8 years 1 month ago #13353
This email address is being protected from spambots. You need JavaScript enabled to view it. forums.delphiforums.com/generichcvtx G 1a F-1 Started tx 10/23/15 (Meso sof & led) ALT 48 AST 28 v/l 1.6 mil 11/17/15 4 wk lab ALT 17 AST 16 <15 11/18/15 Started Harvoni 12/16/15 8 wk lab ALT: 15 AST: 13 V/l UND 1/14/16 Fin. Tx 7/07/16 UND SVR 24 | |
Time to create page: 0.093 seconds